Sarepta Therapeutics (SRPT) Tanks 36% After 3rd Patient Death, SRPT Securities Class Action Pending; Investors With Substantial Losses And Persons With Knowledge Encouraged To Contact Hagens Berman

Core Viewpoint - Sarepta Therapeutics, Inc. experienced a significant decline in share price following the report of a third patient death related to its experimental gene therapy, ELEVIDYS, leading to a 36% drop in stock value on July 18, 2025 [1]. Legal Developments - A securities class action lawsuit has been filed against Sarepta, representing investors who acquired securities between June 22, 2023, and June 24, 2025 [2]. - The lawsuit focuses on Sarepta's disclosures regarding the safety and efficacy of ELEVIDYS, alleging that the company misled investors about the therapy's safety and potential for broader application [4]. Safety Concerns - The complaint highlights that Sarepta failed to disclose critical information regarding the safety of ELEVIDYS, with the first indication of issues arising on March 18, 2025, when a patient death was reported [5]. - Subsequent disclosures included a second patient death on June 15, 2025, and a safety communication from the FDA on June 24, 2025, which investigated the risk of acute liver failure associated with ELEVIDYS [7][8]. Regulatory Actions - Following the reported deaths, the FDA placed Sarepta's clinical trials for both ELEVIDYS and another investigational gene therapy, SRP-9004, on clinical hold [10]. - The company faced increased regulatory scrutiny and was compelled to halt patient recruitment and dosing in its clinical studies due to the severity of adverse events [8]. Financial Impact - The financial press reported a drastic reduction in Sarepta's price target to $0 by H.C. Wainwright following the adverse developments [10].